ACCESS Newswire

Digostics Limited

Share
World-First Introduction of Home Oral Glucose Tolerance Testing Service for Gestational Diabetes Sees University Hospital Southampton Improve Test Accessibility and Yield Maximum User Preference Scores

OXFORD, UK / ACCESSWIRE / February 21, 2024 / Digital clinical diagnostics and diabetes home testing provider Digostics revealed today the results from its ground-breaking gestational diabetes mellitus (GDM) remote screening collaboration with University Hospital Southampton NHS Foundation Trust (UHS), a partnership that saw expectant mothers in Hampshire become the first globally to access the gold standard oral glucose tolerance test (OGTT) without needing to attend clinic.

The initiative, first announced in April 20231, saw women assessed as at risk of developing GDM by their midwife issued with a GTT@home test kit from Digostics to undertake their OGTT at home. The service's introduction saw all women successfully tested in their target test week. Furthermore, 100% of mothers and maternity staff who responded to user surveys recommended GTT@home over traditional clinic-based testing.

The implementation of GTT@home stemmed from an ambition by UHS to improve the quality of the test and to test in a more patient-focused way. Additionally, to enable testing to be undertaken more quickly so that treatment can be initiated sooner where required. Objectives also included reducing the number of antenatal appointments required, freeing up valuable resources and improving healthcare equity of access, particularly for at-risk patient groups.

Improvements in test uptake, quality and reliability, earlier diagnoses and user satisfaction levels, when combined with a significant reduction in OGTT management workload for maternity services, have seen the implementation meet or exceed all agreed success criteria.

"We are constantly trying to balance the critical importance of OGTT provision with the significant human resource and administrative demands in-clinic OGTTs place on us as a busy team." said Rachel Hanley, Community Service Matron, UHS "GTT@home has demonstrated that there is finally another way, one that not only helps ensure prompt and timely access to GDM testing, but that frees up countless valuable midwifery staffing hours to be redirected to other essential antenatal and postnatal activity."

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Rachel Hanley, Community Service Matron, University Hospital Southampton

Up to 20%2 of UK pregnancies are impacted by GDM, with background risk factors including age, ethnicity and body mass index.3 Undiagnosed or untreated, GDM can lead to pregnancy complications that warrant unscheduled or even emergency changes to the birth-plan to protect both mother and baby. GDM also confers an increased risk for both mother4 and child5 of developing Type 2 diabetes later in life and accurate diagnosis with a reliable test is therefore important.

Prior to the implementation of GTT@home, undertaking an OGTT would require women to travel, while fasted, to a dedicated clinic on a specific date and spend over two hours at the hospital. The inconvenience the in-clinic test represents, especially for example for those with childcare pressures, means missed appointments and late tests are frequent. 97% of those using GTT@home found the ability to home test advantageous, with the same percentage welcoming the flexibility to choose which day they tested. 90% found the GTT@home test device easy to use, with no one finding it difficult to use.

"The contribution GTT@home has made to improving OGTT test patient empowerment, equity and accuracy will enable improved care for our patients when GDM is suspected and detected," said Dr Matthew Coleman, Consultant Obstetric Physician at UHS. "In equal parts we are excited that this revolutionary new at-home test is going to dramatically change the way we deliver GDM testing during antenatal care."

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Dr Matthew Coleman, Consultant Obstetric Physician, University Hospital Southampton

In a significant improvement from the in-clinic workflow, which typically sees blood samples only sent to the laboratory for analysis once the final test of the day has been completed, GTT@home ensures both blood tests associated with the OGTT - the initial fasting test and the two-hour test after consumption of a glucose drink - are analysed immediately at the point of testing. This eliminates the sample degradation that can occur between in-clinic blood sampling and laboratory analysis with the traditional OGTT.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
GTT@home Test Kit

After completing a test with GTT@home, the user can send their test data directly to their antenatal care team with a simple scan of a snap-off fob attached to the innovative test device using the GTT@home mobile app and the near field communication (NFC) functionality within their smartphone. Although users can send their test data via a prepaid envelope in the test kit, 98% elected to send their data via their smartphone, with their results available for review by their midwife much faster than could be achieved via the hospital laboratory.

"UHS' pilot implementation of GTT@home has shown that OGTT home testing is not just a viable alternative to in-clinic testing but a significantly more accessible way to screen women for diabetes and potentially improve test accuracy," said Professor Richard Holt, Professor in Diabetes and Endocrinology, University of Southampton.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Prof. Richard Holt, Professor of Diabetes and Endocrinology, The University of Southampton

After the successful pilot of GTT@home at UHS, NHS trusts and health boards nationwide are looking to introduce GTT@home for their pregnant women in 2024. UK-based Digostics is also setting up operations in the Middle East and Asia Pacific to meet the significant demand for GTT@home in these regions and aims to expand to Europe and the USA.

"The results achieved by UHS in having the vision to eliminate barriers to effective GDM screening by taking diabetes testing directly to the mum-to-be speak for themselves," said James Jackson, CEO and Founder of Digostics. "We congratulate our partners at UHS on the success of their GTT@home implementation and for breaking exciting new ground in both global diabetes innovation and women's health."

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
James Jackson, CEO and Founder of Digostics and Inventor of GTT@home

***

Images of Matthew Coleman and of University Hospital Southampton's premises are kindly provided by University Hospital Southampton NHS Foundation Trust. Images of Richard Holt are kindly provided by the University of Southampton.

About Digostics

Far too many people across the world are living with undiagnosed diabetes.

UK-based Digostics' mission is to enable healthcare providers to identify everyone with diabetes, and those at risk of developing diabetes, by eliminating the common barriers that inhibit accurate and timely testing using the gold standard oral glucose tolerance test (OGTT).

Digostics is proud to offer GTT@home - the world's first home OGTT offering and the most accessible and scalable way for clinical teams to realise their diabetes testing objectives.

For more information visit www.digostics.com

About University Hospital Southampton NHS Foundation Trust

University Hospital Southampton NHS Foundation Trust (UHS) is one of the largest acute teaching trusts in England with a turnover of more than £1.15 billion in 2021/22. UHS provides hospital services for 1.9 million people living in southern Hampshire and specialist services - including neurosciences, respiratory medicine, cancer, cardiovascular, obstetrics and specialist children's services - to more than 3.7 million people in central southern England and the Channel Islands. Southampton General Hospital is a designated major trauma centre serving the Wessex Region and Channel Islands and is one of only two places in the south of England to offer adults and children full onsite major trauma care provision.

Every year more than 13,000 staff see 650,000 people at outpatient appointments, deal with 150,000 attendances at the emergency department and treat 160,000 admitted emergency, inpatient or day case patients. In addition, the trust delivers more than 100 outpatient clinics across the south of England to keep services local for patients. Providing these services costs £2.7 million per day.

Following the Care Quality Commission's most recent inspection (report published in April 2019), all sites and services across UHS are now rated as ‘good' or ‘outstanding' in the effective and caring domains. Overall, the trust received a ‘good' rating - and ‘outstanding' for providing effective services. Among individual services, the CQC rated urgent and emergency services, medical care, surgery, services for children and young people and end of life care ‘good‘, with critical care ‘outstanding'. To view the full report, visit www.cqc.org.uk/provider/RHM/reports.

UHS is consistently one of the UK's highest recruiting trusts of patients to clinical trials and in the top ten nationally for research study volume as ranked by the NIHR Clinical Research Network. In partnership with the University of Southampton, UHS has £27 million of NIHR infrastructure dedicated to bringing the latest treatments to patients. For more information, visit www.uhs.nhs.uk/ClinicalResearchinSouthampton.

To help shape the future of hospital services and raise issues that are important to patients, families and visitors, become a UHS member. Anyone interested in finding out more or joining can contact the membership office on www.uhs.nhs.uk/members.

Follow us on Twitter, Facebook, Instagram and LinkedIn for all the latest news updates.

Southampton Hospitals Charity enhances the care and treatment of our patients by raising funds to support areas that lie beyond the scope of NHS funding. For more information, visit www.southamptonhospitalscharity.org

About the University of Southampton

The University of Southampton drives original thinking, turns knowledge into action and impact, and creates solutions to the world's challenges.

We are among the top 100 institutions globally (QS World University Rankings 2023). Our academics are leaders in their fields, forging links with high-profile international businesses and organisations, and inspiring a 22,000-strong community of exceptional students, from over 135 countries worldwide.

Through our high-quality education, the University helps students on a journey of discovery to realise their potential and join our global network of over 200,000 alumni. www.southampton.ac.uk

1 NHS Hospital Trust Pilot of New Testing Technology Sees Pregnant Women in Southampton Become the First Patients Globally to Access Gestational Diabetes Testing at Home.
2 International Diabetes Federation - Diabetes Atlas 10th Edition 2021
3 NHS Gestational Diabetes Overview
4 International Diabetes Federation - Care and Prevention - Gestational Diabetes
5 Pubmed - Future of diabetes in mother and child after gestational diabetes mellitus 2009

Media Contact(s)

Graeme Collins, Digostics
Mobile: +44 (0)7854 664168
Email: gc@digostics.com

University Hospital Southampton NHS Foundation Trust
Email: communications@uhs.nhs.uk

SOURCE: Digostics Limited



View the original press release on accesswire.com

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AGFA HealthCare Strengthens Market Position in KLAS Enterprise Imaging Report 202510.9.2025 22:00:00 CEST | Press release

CARLSTADT, NJ / ACCESS Newswire / September 10, 2025 / AGFA HealthCare has been recognized by KLAS Research for significant satisfaction gains. Customer satisfaction with AGFA's Enterprise Imaging VNA and XERO® Viewer has increased significantly over the past 18 months, with both solutions named Best in KLAS 2025 winners.KLAS Report - Enterprise Imaging 2025 Report highlights: Significant Gains: customer satisfaction with AGFA's VNA increased by 13 points on a 100-point scale over the past 18 months - the largest improvement in the segment. Both VNA and Viewer were named Best in KLAS 2025 winners. Top Scores:XERO® Viewerachieved a 90.0 score, and the Enterprise Imaging VNA reached 87.4 points. Customer Endorsements: respondents praised AGFA for better QA and upgrades, stronger EHR integration and web viewing, and more open dialogue. Customers also noted improved responsiveness, executive check-ins, and proactive account teams. Future Outlook: customers are optimistic about the roadmap,

Sadie's 24/7 AI Receptionist Integrates with OpenTable to Help Restaurants Capture Every Guest Opportunity10.9.2025 17:20:00 CEST | Press release

MONTREAL, QC / ACCESS Newswire / September 10, 2025 / Sadie, the AI-powered voice host for the hospitality industry, today announced a new strategic integration with OpenTable, a global leader in restaurant tech, to offer restaurants a new way to capture booking interest 24/7. For diners, Sadie takes reservations, answers common questions, and provides confirmations and reminders. All activity flows seamlessly into the OpenTable platform, giving restaurants that opt in one connected view of their reservations and guest interactions. "Partnering with OpenTable gives restaurants a powerful advantage: the ability to capture and manage every booking opportunity, no matter how guests choose to connect," said Mitch Bourassa, Partner at Sadie. "By combining OpenTable's network with Sadie's always-on support, we're helping restaurants reduce missed reservations, strengthen guest relationships, and free up staff to focus on the in-person moments that matter most." "Our restaurant partners are c

From the Classroom to the Red Carpet: Maxon Delivers Speed, Flexibility, and Creative Power in a Fresh New Ecosystem Design10.9.2025 16:30:00 CEST | Press release

Maxon One unifies Cinema 4D, ZBrush, Redshift, and Red Giant in bold ecosystem redesign, with tons of new feature capabilities across VFX, 3D modeling, and motion graphics solutions. BAD HOMBURG, GERMANY / ACCESS Newswire / September 10, 2025 / Maxon today unveiled the latest Maxon One release, delivering new innovations across its unified creative ecosystem and introducing a fresh visual identity that is modular, cohesive, and connected. Designed to empower artists at every skill level, from students to seasoned industry veterans, the Fall release streamlines workflows, removes technical barriers, and delivers cutting-edge creative possibilities across VFX, motion graphics, 3D modeling, sculpting, rendering, editing, and more. From cinematic storytelling to broadcast graphics, gaming design to architectural visualization, creators across the full spectrum of disciplines rely on Maxon One for its deeply integrated tools. Cinema 4D now has GPU-accelerated art-directable simulations, whi

Pacific Avenue Capital Partners Advances European Strategy with Team Expansion and Dedicated Sidecar Vehicle10.9.2025 15:00:00 CEST | Press release

PARIS, FR / ACCESS Newswire / September 10, 2025 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm specializing in corporate carve-outs and complex transactions, today announced key milestones in its European expansion. Less than a year after opening its Paris office and appointing Xavier Lambert as Head of Europe, the firm has built a high-caliber team with full execution capabilities. It has also expanded its presence across the region and raised a dedicated sidecar vehicle to support investments in new platforms throughout Europe. Since Mr. Lambert's arrival in late 2024, Pacific Avenue has added seven professionals in Europe across M&A, business development, operations, and administration. In addition to its Paris office, the firm now has team members in London and Zurich, enhancing its ability to source and support transactions across the continent. The team's diverse experience positions the firm to navigate complexity and drive value across a bro

Karbon-X and Banff Half Marathon Celebrate 2025 with Verified Climate Contributions that Reflect the Spirit of the Rockies10.9.2025 15:00:00 CEST | Press release

Three years strong: Karbon-X and the Banff Half Marathon continue to deliver measurable climate action through verified contributions CALGARY, AB / ACCESS Newswire / September 10, 2025 / For the third consecutive year, Karbon-X (OTCQX:KARX) and the Banff Half Marathon have partnered to take meaningful, measurable climate action that reflects the natural values of the Rockies. This year's race included verified climate contributions covering the event's footprint, along with voluntary contributions made by runners at registration. By choosing an optional add-on at checkout, participants were able to make a personal impact, integrating climate action directly into their race experience. The story behind this effort is as local as it is global. Banff has long lived in rhythm with nature, from the early hydro stations that powered mountain towns to campfires that bring people together after a day outdoors. The climate contributions made through this partnership echo that legacy, supporting

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye